

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJRK1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 MAY 01 New CAS web site launched
NEWS 3 MAY 08 CA/Capplus Indian patent publication number format defined
NEWS 4 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 5 MAY 21 BIOSIS reloaded and enhanced with archival data
NEWS 6 MAY 21 TOXCENTER enhanced with BIOSIS reload
NEWS 7 MAY 21 CA/Capplus enhanced with additional kind codes for German patents
NEWS 8 MAY 22 CA/Capplus enhanced with IPC reclassification in Japanese patents
NEWS 9 JUN 27 CA/Capplus enhanced with pre-1967 CAS Registry Numbers
NEWS 10 JUN 29 STN Viewer now available
NEWS 11 JUN 29 STN Express, Version 8.2, now available
NEWS 12 JUL 02 LEMBASE coverage updated
NEWS 13 JUL 02 LMEDLINE coverage updated
NEWS 14 JUL 02 SCISEARCH enhanced with complete author names
NEWS 15 JUL 02 CHEMCATS accession numbers revised
NEWS 16 JUL 02 CA/Capplus enhanced with utility model patents from China
NEWS 17 JUL 16 CAplus enhanced with French and German abstracts
NEWS 18 JUL 18 CA/Capplus patent coverage enhanced
NEWS 19 JUL 26 USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 20 JUL 30 USGENE now available on STN
NEWS 21 AUG 06 CAS REGISTRY enhanced with new experimental property tags
NEWS 22 AUG 06 BEILSTEIN updated with new compounds
NEWS 23 AUG 06 FSTA enhanced with new thesaurus edition
NEWS 24 AUG 13 CA/Capplus enhanced with additional kind codes for granted patents
NEWS 25 AUG 20 CA/Capplus enhanced with CAS indexing in pre-1907 records
NEWS 26 AUG 27 Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 27 AUG 27 USPATOLD now available on STN
NEWS 28 AUG 28 CAS REGISTRY enhanced with additional experimental spectral property data

NEWS 29 SEP 07 STN AnaVist, Version 2.0, now available with Derwent World Patents Index

NEWS EXPRESS 05 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:14:51 ON 11 SEP 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 15:15:07 ON 11 SEP 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 10 SEP 2007 HIGHEST RN 946567-47-1

DICTIONARY FILE UPDATES: 10 SEP 2007 HIGHEST RN 946567-47-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10520621\Struc 7.str



chain nodes :

10520621a.trn

Page 3

6 14 15
ring nodes :
1 2 3 4 5 7 8 9 10 11 12 17 18 19 20
chain bonds :
2-14 3-6 5-15 6-7
ring bonds :
1-2 1-5 2-3 3-4 4-5 7-8 7-12 8-9 9-10 9-17 10-11 10-20 11-12 17-18
18-19 19-20
exact/norm bonds :
1-2 1-5 2-3 2-14 3-4 4-5 5-15
exact bonds :
3-6 6-7
normalized bonds :
7-8 7-12 8-9 9-10 9-17 10-11 10-20 11-12 17-18 18-19 19-20

G1:O,S,N

Match level :


1:Atom 2:Atom 3:Atom 4:CLASS 5:Atom 6:CLASS 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 14:CLASS 15:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> l1

SAMPLE SEARCH INITIATED 15:15:19 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 4 TO ITERATE

100.0% PROCESSED 4 ITERATIONS
SEARCH TIME: 00.00.01

2 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 4 TO 200

10520621a.trn

Page 4

PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> 11 full

FULL SEARCH INITIATED 15:15:22 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 42 TO ITERATE

100.0% PROCESSED 42 ITERATIONS

24 ANSWERS

SEARCH TIME: 00.00.01

L3 24 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.10

172.31

FILE 'CAPLUS' ENTERED AT 15:15:24 ON 11 SEP 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Sep 2007 VOL 147 ISS 12

FILE LAST UPDATED: 10 Sep 2007 (20070910/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> 13

L4 3 L3

=> d ibib abs hitstr 1-3

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:367076 CAPLUS
 DOCUMENT NUMBER: 144:398358
 TITLE: PI3 kinase gamma inhibitors for the treatment of
 anaemia
 INVENTOR(S): Metzker, Reinhard; Mueller, Angelika; Rommel,
 Christian
 PATENT ASSIGNEE(S): Applied Research Systems Ars Holding N.V., Neth.
 Antilles
 SOURCE: PCT Int. Appl., 48 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|----------|
| WO 2006040318 | A2 | 20060420 | WO 2005-EP55156 | 20051011 |
| WO 2006040318 | A3 | 20060810 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, CA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM


AU 2005293556 A1 20060420 AU 2005-293556 20051011
 CA 2580480 A1 20060420 CA 2005-2580480 20051011
 EP 1807075 A2 20070718 EP 2005-801722 20051011

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU


IN 2007DN02450 A 20070803 IN 2007-DN2450 20070402
 NO 2007002393 A 20070509 NO 2007-2393 20070509
 EP 2004-104997 A 20041012

PRIORITY APPL. INFO.: WO 2005-EP55156 W 20051011


OTHER SOURCE(S): HARPAT 144:398358
 GI




L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 648449-86-9 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-(1-piperidinyl)-6-quinazolinyl]methylene]- (9CI) (CA INDEX NAME)



RN 648449-87-0 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-(4-morpholinyl)-6-quinazolinyl]methylene]- (9CI) (CA INDEX NAME)



RN 648449-88-1 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(phenylmethyl)amino]-6-quinazolinyl]methylene]- (9CI) (CA INDEX NAME)



RN 648449-89-2 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-(diethylamino)-6-quinazolinyl]methylene]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

AB This present invention is related to the use of selective PD kinase gamma inhibitors for the manufacture of a medicament for the treatment of disorders

related to erythrocyte deficiency. Specifically, the present invention

is related to the use of selective PI3 Kinase gamma inhibitors, e.g. substituted azolidinone-vinyl fused-benzene derivs. for the treatment of an anemia, including haemolytic anemia, aplastic anemia and pure red cell anemia. (I) wherein A, X, Y1, Y2, Z, n, R1 and R2 are described in details in the description hereinafter.


IT 648449-83-6 648449-84-7 648449-85-8
 648449-86-9 648449-87-0 648449-88-1
 648449-89-2 648449-90-5 648449-91-6
 648449-92-7 648449-93-8 648449-94-9
 648449-95-0 648449-96-1 648449-97-2
 648449-98-3 648449-99-4 648450-00-4
 648450-01-5 648450-02-6 648450-03-7
 648450-05-9 648450-06-0 648915-80-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(PI3 Kinase gamma inhibitors for treatment of anemia)


RN 648449-83-6 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-(phenyl-6-quinazolinyl)methylene]- (9CI) (CA INDEX NAME)



RN 648449-84-7 CAPLUS


CN 2,4-Thiazolidinedione, 5-[[4-(dimethylamino)-6-quinazolinyl]methylene]- (9CI) (CA INDEX NAME)



RN 648449-85-8 CAPLUS


CN 2,4-Thiazolidinedione, 5-[[4-(amino-6-quinazolinyl)methylene]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 648449-90-5 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(2-pyridinylmethyl)amino]-6-quinazolinyl]methylene]- (9CI) (CA INDEX NAME)



RN 648449-91-6 CAPLUS


CN 2,4-Thiazolidinedione, 5-[[4-[(3-pyridinylmethyl)amino]-6-quinazolinyl]methylene]- (9CI) (CA INDEX NAME)




RN 648449-92-7 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[6-[[2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinazolinyl]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 648449-93-8 CAPLUS
 CN 4-Piperidinecarboxylic acid,
 1-[6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-
 4-quinazolinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 648449-94-9 CAPLUS
 CN L-Proline,
 1-[6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinazolinyl]-,
 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.




L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 648449-98-3 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-(4-(phenylmethyl)-1-piperidinyl)-6-
 quinazolinyl]methylene]- (9CI) (CA INDEX NAME)




RN 648449-99-4 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-(4-(2-phenylethyl)-1-piperidinyl)-6-
 quinazolinyl]methylene]- (9CI) (CA INDEX NAME)




RN 648450-00-4 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-(4-methyl-1-piperidinyl)-6-
 quinazolinyl]methylene]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 648449-95-0 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-(4-methyl-1-piperazinyl)-6-
 quinazolinyl]methylene]- (9CI) (CA INDEX NAME)




RN 648449-96-1 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-(4-(2-pyrimidinyl)-1-piperazinyl)-6-
 quinazolinyl]methylene]- (9CI) (CA INDEX NAME)




RN 648449-97-2 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-(4-(4-fluorophenyl)-1-piperidinyl)-6-
 quinazolinyl]methylene]- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 648450-01-5 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-(4-(4-hydroxy-1-piperidinyl)-6-
 quinazolinyl]methylene)- (9CI) (CA INDEX NAME)




RN 648450-02-6 CAPLUS
 CN 4-Piperidinecarboxylic acid,
 1-[6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-
 4-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 648450-03-7 CAPLUS
 CN 3-Piperidinecarboxylic acid,
 1-[6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-
 4-quinazolinyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 648450-05-9 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(4-(methylamino)-6-quinazolinyl)methylene]- (9CI) (CA INDEX NAME)



RN 648450-06-0 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(4-methoxy-6-quinazolinyl)methylene]- (9CI) (CA INDEX NAME)



RN 648915-80-4 CAPLUS
CN L-Proline, 1-[6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinazolinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:60505 CAPLUS
DOCUMENT NUMBER: 140:128412
TITLE: Preparation of azolidinone-vinyl fused-benzene derivatives for therapeutic uses as PI3 kinase inhibitors
INVENTOR(S): Rueckle, Thomas; Jiang, Xuliang; Gaillard, Pascale; Church, Dennis; Vallotton, Tania
PATENT ASSIGNER(S): Applied Research Systems Ars Holding N.V., Neth. Antilles
SOURCE: PCT Int. Appl., 142 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2004007491 | A1 | 20040122 | WO 2003-EP50302 | 20030710 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, ME, SD, SL, SE, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2004092561 | A1 | 20040513 | US 2002-289998 | 20021107 |
| CA 2493843 | A1 | 20040122 | CA 2003-2493843 | 20030710 |
| AU 2003255528 | A1 | 20040202 | AU 2003-255528 | 20030710 |
| BR 2003012752 | A | 20050426 | BR 2003-12752 | 20030710 |
| BR 2003012650 | A | 20050503 | BR 2003-12650 | 20030710 |
| EP 1549644 | A1 | 20050706 | EP 2003-763907 | 20030710 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| CN 1681811 | A | 20051012 | CN 2003-821416 | 20030710 |
| JP 2005538188 | T | 20051215 | JP 2005-505076 | 20030710 |
| ZA 2005000162 | A | 20060726 | ZA 2005-162 | 20050107 |
| MX 20050400453 | A | 20050323 | MX 2005-PA453 | 20050110 |
| NO 2005000654 | A | 20050315 | NO 2005-654 | 20050208 |
| US 2006122176 | A1 | 20060608 | US 2005-520621 | 20050824 |
| PRIORITY APPLN. INFO.: | | | EP 2002-100798 | A 20020710 |
| | | | US 2002-289998 | A 20021107 |
| | | | WO 2003-EP50302 | W 20030710 |

OTHER SOURCE(S): MARPAT 140:128412
GI

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB The present invention is related to the preparation of azolidinone-vinyl fused-benzene derivs., such as I (R1 = H, CH, carboxy, acyl, alkoxy, halogen, acyloxy, etc.); A = fused heterocyclic or carbocyclic ring; Y1, Y2 = S, O, NH), and their use in pharmaceutical compns. as PI3 kinase (PI3K) inhibitors. These azolidinones are claimed for use in the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, cancer, graft rejection, lung injuries, chronic obstructive pulmonary disease, anaphylactic shock, fibrosis, psoriasis, allergic diseases, asthma, stroke or ischemic conditions, ischemia-reperfusion, platelet aggregation/activation, skeletal muscle atrophy/hypertrophy, leukocyte recruitment in cancer tissue, angiogenesis, invasion metastasis in melanoma and Kaposi's sarcoma, sepsis, transplantation, pancreatitis, multi-organ failure, glomerulosclerosis, glomerulonephritis, progressive renal fibrosis, endothelial and epithelial injuries in the lung or in general lung airways inflammation. Further, these azolidinones are claimed for use in the treatment of atherosclerosis, hypertrophy, cardiac myocyte dysfunction, elevated blood pressure, vasoconstriction, Alzheimer's disease, Huntington's disease, CNS trauma, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, thrombosis, and brain infection/inflammation such as meningitis or encephalitis. Thus, azolidinone II was prepared via a condensation reaction of piperonal with 2,4-thiazolidinedione using D-alanine in acetic acid and stirring at 100° for 3 h. Some of the prepared azolidinones were assayed for PI3K inhibition using a high throughput PI3K lipid kinase binding assay. Tablet, capsule, liquid and injectable pharmaceutical compns. were presented.

IT 648449-93-8P 648449-94-9P
RI: PAC (Pharmacological Activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of azolidinone-vinyl fused-benzene derivs. for use in pharmaceutical compns. as PI3 kinase inhibitors)


RN 648449-93-8 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinazolinyl]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 648449-94-9 CAPLUS
CN L-Proline,
1-[[6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinazolinyl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




IT 648449-83-6P 648449-84-7P 648449-85-8P
648449-86-9P 648449-87-0P 648449-88-1P
648449-89-2P 648449-90-5P 648449-91-6P
648449-92-7P 648449-95-0P 648449-96-1P
648449-97-2P 648449-98-3P 648449-99-4P
648450-00-4P 648450-01-5P 648450-02-6P
648450-03-7P 648450-05-9P 648450-06-0P
648915-80-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(Preparation of azolidinone-vinyl fused-benzene derivs. for use in
pharmaceutical compns. as PI3 kinase inhibitors)
RN 648449-83-6 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-(4-phenyl-6-quinazolinyl)methylene]- (9CI) (CA
INDEX NAME)


L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 648449-88-1 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[(phenylmethyl)amino]-6-
quinazolinyl)methylene]- (9CI) (CA INDEX NAME)



RN 648449-89-2 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-(diethylamino)-6-quinazolinyl)methylene]-
(9CI) (CA INDEX NAME)




RN 648449-90-5 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[(2-pyridinylmethyl)amino]-6-
quinazolinyl)methylene]- (9CI) (CA INDEX NAME)




RN 648449-91-6 CAPLUS

10520621a.trn


L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 648449-84-7 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-(dimethylamino)-6-quinazolinyl)methylene]-
(9CI) (CA INDEX NAME)



RN 648449-85-8 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-(4-amino-6-quinazolinyl)methylene]- (9CI) (CA
INDEX NAME)




RN 648449-86-9 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-(1-piperidinyl)-6-quinazolinyl)methylene]-
(9CI) (CA INDEX NAME)




RN 648449-87-0 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-(4-morpholinyl)-6-quinazolinyl)methylene]-
(9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 2,4-Thiazolidinedione, 5-[[4-[(3-pyridinylmethyl)amino]-6-
quinazolinyl)methylene]- (9CI) (CA INDEX NAME)



RN 648449-92-7 CAPLUS
CN 3-Piperidinecarboxylic acid,
1-[[6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-
4-quinazolinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 648449-95-0 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-(4-methyl-1-piperazinyl)-6-
quinazolinyl)methylene]- (9CI) (CA INDEX NAME)




RN 648449-96-1 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[(2-pyrimidinyl)-1-piperazinyl]-6-
quinazolinyl)methylene]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 648449-97-2 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(4-fluorophenyl)-1-piperidinyl]-6-quinazolinyl]methylene]- (9CI) (CA INDEX NAME)




RN 648449-98-3 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(phenylmethyl)-1-piperidinyl]-6-quinazolinyl]methylene]- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 648449-99-4 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(2-phenylethyl)-1-piperidinyl]-6-quinazolinyl]methylene]- (9CI) (CA INDEX NAME)




RN 648450-00-4 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(4-methyl-1-piperidinyl)-6-quinazolinyl]methylene]- (9CI) (CA INDEX NAME)




RN 648450-01-5 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(4-hydroxy-1-piperidinyl)-6-quinazolinyl]methylene]- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 648450-02-6 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-[6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 648450-03-7 CAPLUS
 CN 3-Piperidinecarboxylic acid, 1-[6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 648450-05-9 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(methylamino)-6-quinazolinyl]methylene]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 648450-06-0 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[(methoxy-6-quinazolinyl]methylene]- (9CI) (CA INDEX NAME)



RN 648915-80-4 CAPLUS
 CN L-Proline, 1-[6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinazolinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN


ACCESSION NUMBER: 2004:60305 CAPLUS
 DOCUMENT NUMBER: 140:128411
 TITLE: Preparation of dioxothiazolidenemethyl derivatives for increasing spermatozoa motility
 INVENTOR(S): De Luca, Giampiero
 PATENT ASSIGNEE(S): Applied Research Systems Ars Holding NV, Neth.
 SOURCE: Antilles
 PCT Int. Appl., 131 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY-ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-----------------------|--|----------|-----------------|------------|
| WO 2004006916 | A1 | 20040122 | WO 2003-EP50303 | 20030710 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, T, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| CA 2489779 | A1 | 20040122 | CA 2003-2489779 | 20030710 |
| AU 2003255529 | A1 | 20040202 | AU 2003-255529 | 20030710 |
| EP 1531813 | A1 | 20050525 | EP 2003-763908 | 20030710 |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | |
| JP 2006500327 | T | 20060105 | JP 2004-520680 | 20030710 |
| NO 200500071 | A | 20050210 | NO 2005-713 | 20050210 |
| US 2005222225 | A1 | 20051006 | US 2005-519685 | 20050504 |
| PRIORITY APPL. INFO.: | | | EP 2002-100799 | A 20020710 |
| | | | EP 2002-102876 | A 20021223 |
| | | | WO 2003-EP50303 | W 20030710 |

OTHER SOURCE(S): MARPAT 140:128411
 GI




L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 648449-83-6P, 5-[(4-Phenylquinazolin-6-yl)methylene]thiazolidine-2,4-dione 648449-84-7P, 5-[(4-Dimethylaminoquinazolin-6-yl)methylene]thiazolidine-2,4-dione 648449-85-8P, 5-[(4-Aminoquinazolin-6-yl)methylene]thiazolidine-2,4-dione 648449-86-9P, 5-[(4-Piperidin-1-yl)quinazolin-6-yl)methylene]thiazolidine-2,4-dione 648449-87-0P, 5-[(4-Morpholin-4-yl)quinazolin-6-yl)methylene]thiazolidine-2,4-dione 648449-88-1P, 5-[(4-Benzylamino)quinazolin-6-yl)methylene]thiazolidine-2,4-dione 648449-89-2P, 5-[(4-Diethylamino)quinazolin-6-yl)methylene]thiazolidine-2,4-dione 648449-90-5P, 5-[(4-[(Pyridin-2-yl)methyl]amino)quinazolin-6-yl)methylene]thiazolidine-2,4-dione 648449-91-6P, 5-[(4-[(Pyridin-3-yl)methyl]amino)quinazolin-6-yl)methylene]thiazolidine-2,4-dione 648449-92-7P, Ethyl 1-[6-[(2,4-dioxothiazolidin-5-ylidene)methyl]quinazolin-4-yl]piperidine-3-carboxylate 648449-95-0P, 5-[(4-(4-Methylpiperazin-1-yl)quinazolin-6-yl)methylene]thiazolidine-2,4-dione 648449-96-1P, 5-[(4-(4-Pyrimidin-2-yl)piperazin-1-yl)quinazolin-6-yl)methylene]thiazolidine-2,4-dione 648449-97-2P, 5-[(4-(4-Fluorophenyl)piperidin-1-yl)quinazolin-6-yl)methylene]thiazolidine-2,4-dione 648449-98-3P, 5-[(4-(4-Benzylpiperidin-1-yl)quinazolin-6-yl)methylene]thiazolidine-2,4-dione 648449-99-4P, 5-[(4-(4-(2-Phenylethyl)piperidin-1-yl)quinazolin-6-yl)methylene]thiazolidine-2,4-dione 648450-00-4P
 5-[(4-(4-Methylpiperidin-1-yl)quinazolin-6-yl)methylene]thiazolidine-2,4-dione 648450-01-5P, 5-[(4-(4-Hydroxypiperidin-1-yl)quinazolin-6-yl)methylene]thiazolidine-2,4-dione 648450-02-6P, 1-[6-(2,4-Dioxothiazolidin-5-ylidene)methyl]quinazolin-4-yl]piperidine-4-carboxylic acid 648450-03-7P, 1-[6-(2,4-Dioxothiazolidin-5-ylidene)methyl]quinazolin-4-yl]piperidine-3-carboxylic acid 648450-05-9P, 5-(4-Methylaminoquinazolin-6-yl)methylene]thiazolidine-2,4-dione 648450-06-0P, 5-(4-Methoxyquinazolin-6-yl)methylene]thiazolidine-2,4-dione 648450-07-1P, 1-[6-(2,4-Dioxothiazolidin-5-ylidene)methyl]quinazolin-4-yl]pyrrolidine-2-carboxylic acid
 RI: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Preparation of dioxothiazolidenemethyl deriva. for increasing spermatozoa motility)
 RN 648449-83-6 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[(4-phenyl-6-quinazolinyl)methylene]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


AB Title compds. I [X = S, O, NH; Y1-2 = S, O, NH; Cy = 5-8 membered, optionally fused, carbo/heterocyclic ring] are prepared. For instance, thiazolidine-2,4-dione is condensed with piperonal (HOAc, β -alanine, 3 h, 100°C) to give II. Selected examples have IC50 < 1 μ M for the phosphatidylinositol-3-kinase (PI3K) receptor. I are useful for the improvement of spermatozoa fertilization activity; in particular for the increase of spermatozoa motility. Furthermore, I are used to treat infertility and assisted reproduction techniques (ART).
 IT 648449-93-8P, Ethyl 1-[6-[(2,4-dioxothiazolidin-5-ylidene)methyl]quinazolin-4-yl]piperidine-4-carboxylate 648449-94-9P
 RI: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (Preparation of dioxothiazolidenemethyl deriva. for increasing spermatozoa motility)
 RN 648449-93-8 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-[6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinazolinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 648449-94-9 CAPLUS
 CN L-Proline, 1-[6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinazolinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 648449-84-7 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[(4-(dimethylamino)-6-quinazolinyl)methylene]- (9CI) (CA INDEX NAME)



RN 648449-85-8 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[(4-amino-6-quinazolinyl)methylene]- (9CI) (CA INDEX NAME)




RN 648449-86-9 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[(4-(1-piperidinyl)-6-quinazolinyl)methylene]- (9CI) (CA INDEX NAME)




RN 648449-87-0 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[(4-(4-morpholinyl)-6-quinazolinyl)methylene]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 648449-88-1 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[(phenylmethyl)amino]-6-quinazolinyl]methylene]- (9CI) (CA INDEX NAME)




RN 648449-89-2 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[(diethylamino)-6-quinazolinyl]methylene]- (9CI) (CA INDEX NAME)




RN 648449-90-5 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[(2-pyridinylmethyl)amino]-6-quinazolinyl]methylene]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 648449-95-0 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[(4-methyl-1-piperazinyl)-6-quinazolinyl]methylene]- (9CI) (CA INDEX NAME)




RN 648449-96-1 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[(2-pyrimidinyl)-1-piperazinyl]-6-quinazolinyl]methylene]- (9CI) (CA INDEX NAME)




RN 648449-97-2 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[(4-fluorophenyl)-1-piperidinyl]-6-quinazolinyl]methylene]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 648449-91-6 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[(3-pyridinylmethyl)amino]-6-quinazolinyl]methylene]- (9CI) (CA INDEX NAME)




RN 648449-92-7 CAPLUS
CN 3-Piperidinecarboxylic acid, 1-[6-[[2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinazolinyl]-, ethyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 648449-98-3 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[(4-methyl-1-piperazinyl)-6-quinazolinyl]methylene]- (9CI) (CA INDEX NAME)




RN 648449-99-4 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[(2-phenylethyl)-1-piperidinyl]-6-quinazolinyl]methylene]- (9CI) (CA INDEX NAME)




RN 648450-00-4 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[(4-methyl-1-piperidinyl)-6-quinazolinyl]methylene]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 648450-01-5 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-(4-hydroxy-1-piperidinyl)-6-quinazolinyl]methylene]- (9CI) (CA INDEX NAME)




RN 648450-02-6 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-[6-[[2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 648450-03-7 CAPLUS
 CN 3-Piperidinecarboxylic acid, 1-[6-[[2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinazolinyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 648450-05-9 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-(4-methylamino)-6-quinazolinyl]methylene]- (9CI) (CA INDEX NAME)



RN 648450-06-0 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-(4-methoxy-6-quinazolinyl)methylene]- (9CI) (CA INDEX NAME)



RN 648915-80-4 CAPLUS
 CN L-Proline, 1-[6-[[2,4-dioxo-5-thiazolidinylidene)methyl]-4-quinazolinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.

Page 13

=> log h

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

16.28

188.59

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-2.34

-2.34

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 15:15:39 ON 11 SEP 2007